Mektovi

Active Ingredient(s): Binimetinib
FDA Approved: * June 27, 2018
Pharm Company: * ARRAY BIOPHARMA INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Mektovi Overview

Binimetinib, also known as Mektovi and ARRY-162, is an anti-cancer small molecule that was developed by Array Biopharma to treat various cancers.[1] Binimetinib is a selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway.[2] Inappropriate activation of the pathway has been shown to occur in many cancers.[2] In June 2018 it was approved by the FDA in combination with encorafenib for the treatment of patients with unresec...

Read more Mektovi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Binimetinib

Recent Mektovi Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Binimetinib
  • Tablet: 15mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Mektovi: (1 result)

Sorted by National Drug Code
  • 70255-010 Mektovi 15 mg Oral Tablet, Film Coated by Array Biopharma Inc.

Other drugs which contain Binimetinib or a similar ingredient: (1 result)